Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
about
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapyDiagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature reviewDoes a positive anti-CCP test identify a distinct arthritis entity?The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesAutoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodiesAntibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significanceAutoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis.Constitutively altered frequencies of circulating follicullar helper T cell counterparts and their subsets in rheumatoid arthritisAdalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis.Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritisA systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritisAntibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.The lung may play a role in the pathogenesis of rheumatoid arthritis.High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritisBest practice in primary care pathology: review 6.Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display.Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case studyChanges in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis.The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.Rheumatoid factors: clinical applications.Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis.Autoantibodies to posttranslational modifications in rheumatoid arthritis.Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis.Biomarkers of rheumatoid arthritis: recent progress.Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity.Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.Anti-cyclic citrullinated Peptide antibody: an early diagnostic and prognostic biomarker of rheumatoid arthritisAge-related diagnostic utility of rheumatoid factor, anticyclic citrullinated peptide and antikeratin antibodies in Chinese patients with rheumatoid arthritis.Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.Association of MTHFR C677T and A1298C gene polymorphisms with methotrexate efficiency and toxicity in Algerian rheumatoid arthritis patients.Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.
P2860
Q21195370-17F06046-6482-44DC-9808-F0050C560AB4Q24675281-F6975D1F-E6ED-40FD-ABE6-041A88D1FFD5Q24812995-30CE8DBB-0082-4A04-84E2-01F84391F4ECQ27022645-DCB8CEA9-3D64-4139-BEE5-5C269582F7FAQ33673310-2F6E23EB-1AA7-4AA6-9DF5-EC0C544B2874Q33893385-F4B675C7-6116-4EC5-88F5-A602B11AEAA6Q34159040-FBED068E-69AF-4943-AA59-973CBD3B1A06Q34768971-EDEE4949-C75C-4C1C-9C75-2763E82F32D4Q34896439-96F52875-EFC8-426C-AADD-D7847373BBC6Q34897056-E9777D5C-A4A5-4849-8309-4AF9E1E74BA5Q35067205-6F970B3E-9711-49EE-AE82-CB419DF2DFB9Q35207886-F028957B-EEFF-47B0-A93D-14BBD175492BQ35475541-23C821E2-E79C-45F7-A337-4ED082960876Q35636615-13CE5D44-6524-4F2E-94B2-B6AB8ECAA1BAQ35637041-8D86B19D-E75C-4BA9-8993-913993331A21Q35645491-0C5B0EF7-8A83-4F73-BABB-60D506E871D9Q35747705-9D41539F-2D27-4B92-982D-E75DE53B55DDQ35760039-6E9D4322-183F-4905-AA11-3C2C6A50E9B7Q35770502-08C6C05F-9EB4-4FD5-8C64-E35BDD3E1FBCQ35825343-30A5EEFB-D69F-4B81-BB1B-47599EA9C977Q36401901-80BDB39C-A242-4694-BCB0-17D45F6CB230Q36577396-44333ACD-3C5F-4BFB-A9A7-7131D5F755B4Q36740473-B776E1F0-8B49-453A-8B87-8F9F9AE0FFB0Q37280952-47DEB2B1-FA15-4BB6-9993-4580739916E2Q37353700-85D3BBDF-F4E9-4CB9-9D36-E887BAB62F7BQ37453967-ACA03487-46D9-412A-B034-DA130D4AF1B7Q37693939-24EF7D7C-74A0-4661-A728-C016ED7D998DQ37720317-DBEC909C-5A21-448F-A0A0-41B032E5B551Q38089869-66DFDD22-2345-42D9-A710-5B77F071F268Q38855074-C6A4026D-5721-4BC3-A8D2-7EC166EE149EQ39042536-94EA3A30-2D35-498E-B584-660240A42CBDQ39603215-43512532-E50D-44A9-B84E-18F0C033B52CQ40119794-23061967-251B-4743-A37F-C86106EC8215Q42036955-1AF6A066-4942-4523-A8F6-3A76DF2F9302Q43633174-367B29EF-EC51-4BAC-8746-477E6E2055E4Q46401991-B3E3E35D-E940-4EBE-AA7F-E487B7BFEB6EQ47134001-035CE133-EF22-4AEE-9C8E-71347A58E567Q50879100-3728AF70-CBFF-4CB0-AA0B-225CE920F0BE
P2860
Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Association of rheumatoid arth ...... itrullinated peptide antibody.
@en
Association of rheumatoid arth ...... itrullinated peptide antibody.
@nl
type
label
Association of rheumatoid arth ...... itrullinated peptide antibody.
@en
Association of rheumatoid arth ...... itrullinated peptide antibody.
@nl
prefLabel
Association of rheumatoid arth ...... itrullinated peptide antibody.
@en
Association of rheumatoid arth ...... itrullinated peptide antibody.
@nl
P2093
P356
P1476
Association of rheumatoid arth ...... itrullinated peptide antibody.
@en
P2093
Parrish LA
P304
P356
10.1002/ART.20659
P577
2004-12-01T00:00:00Z